Shukuya et al. analyzed miRNA profiles by NGS in plasma and plasma extracellular vesicles (EV) from advanced NSCLC patients prior to initiation of anti-PD-1 or anti-PD-L1 targeting therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.